Literature DB >> 22860169

Fragile X syndrome: an update on developing treatment modalities.

Aileen Healy1, Roger Rush, Timothy Ocain.   

Abstract

Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.

Entities:  

Keywords:  Fragile X syndrome; fragile X mental retardation gene; fragile X mental retardation protein; metabotropic glutamate receptor 5; γ-aminobutyric acid

Mesh：

Substances：

Year:  2011        PMID： 22860169      PMCID： PMC3369755          DOI： 10.1021/cn200019z

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  102 in total

1.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1.

Authors:  K M Huber; J C Roder; M F Bear
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

Review 2.  Recent progress in the development of allosteric modulators of mGluR5.

Authors:  Alice L Rodriguez; Richard Williams
Journal:  Curr Opin Drug Discov Devel       Date:  2007-11

3.  Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs.

Authors:  Gábor Wágner; Csaba Wéber; Olga Nyéki; Katalin Nógrádi; Attila Bielik; László Molnár; Amrita Bobok; Attila Horváth; Béla Kiss; Sándor Kolok; József Nagy; Dalma Kurkó; Krisztina Gál; István Greiner; Zsolt Szombathelyi; György M Keseru; György Domány
Journal:  Bioorg Med Chem Lett       Date:  2010-04-22       Impact factor: 2.823

4.  Open-label riluzole in fragile X syndrome.

Authors:  Craig A Erickson; Ning Weng; Ivan Jeanne Weiler; William T Greenough; Kimberly A Stigler; Logan K Wink; Christopher J McDougle
Journal:  Brain Res       Date:  2010-11-05       Impact factor: 3.252

5.  Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5.

Authors:  Peng Zhang; Mu-Fa Zou; Alice L Rodriguez; P Jeffrey Conn; Amy Hauck Newman
Journal:  Bioorg Med Chem       Date:  2010-03-27       Impact factor: 3.641

6.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation.

Authors:  I J Weiler; S A Irwin; A Y Klintsova; C M Spencer; A D Brazelton; K Miyashiro; T A Comery; B Patel; J Eberwine; W T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

7.  A nuclear role for the Fragile X mental retardation protein.

Authors:  R A Fridell; R E Benson; J Hua; H P Bogerd; B R Cullen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

8.  Stress induced changes in cortical and hypothalamic c-fos expression are altered in fragile X mutant mice.

Authors:  Julie C Lauterborn
Journal:  Brain Res Mol Brain Res       Date:  2004-11-24

9.  Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5.

Authors:  Douglas F Burdi; Rachel Hunt; Lei Fan; Tao Hu; Jun Wang; Zihong Guo; Zhiqiang Huang; Chengde Wu; Larry Hardy; Michel Detheux; Michael A Orsini; Maria S Quinton; Robert Lew; Kerry Spear
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

10.  Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5.

Authors:  Andrew S Felts; Sam A Saleh; Uyen Le; Alice L Rodriguez; C David Weaver; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2009-10-09       Impact factor: 2.823
View more
  10 in total

1.  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.

Authors:  Bruce J Melancon; Thomas J Utley; Christian Sevel; Margrith E Mattmann; Yiu-Yin Cheung; Thomas M Bridges; Ryan D Morrison; Douglas J Sheffler; Colleen M Niswender; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2012-06-15       Impact factor: 2.823

2.  Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.

Authors:  Bruce J Melancon; Alexander P Lamers; Thomas M Bridges; Gary A Sulikowski; Thomas J Utley; Douglas J Sheffler; Meredith J Noetzel; Ryan D Morrison; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2011-12-06       Impact factor: 2.823

3.  Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.

Authors:  Andreea S Pop; Josien Levenga; Celine E F de Esch; Ronald A M Buijsen; Ingeborg M Nieuwenhuizen; Tracy Li; Aaron Isaacs; Fabrizio Gasparini; Ben A Oostra; Rob Willemsen
Journal:  Psychopharmacology (Berl)       Date:  2012-12-21       Impact factor: 4.530

Review 4.  ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-07-06       Impact factor: 4.418

5.  GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome.

Authors:  D Sinclair; R Featherstone; M Naschek; J Nam; A Du; S Wright; K Pance; O Melnychenko; R Weger; S Akuzawa; M Matsumoto; S J Siegel
Journal:  eNeuro       Date:  2017-03-01

Review 6.  New Targeted Treatments for Fragile X Syndrome.

Authors:  Dragana Protic; Maria J Salcedo-Arellano; Jeanne Barbara Dy; Laura A Potter; Randi J Hagerman
Journal:  Curr Pediatr Rev       Date:  2019

7.  Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells.

Authors:  Zahra Fazeli; Sayyed Mohammad Hossein Ghaderian; Hossein Najmabadi; Mir Davood Omrani
Journal:  Iran J Child Neurol       Date:  2022-01-01

8.  Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2.

Authors:  Argel Aguilar-Valles; Edna Matta-Camacho; Arkady Khoutorsky; Christos Gkogkas; Karim Nader; Jean-Claude Lacaille; Nahum Sonenberg
Journal:  J Neurosci       Date:  2015-08-05       Impact factor: 6.167

Review 9.  Epigenetic findings in autism: new perspectives for therapy.

Authors:  Dario Siniscalco; Alessandra Cirillo; James Jeffrey Bradstreet; Nicola Antonucci
Journal:  Int J Environ Res Public Health       Date:  2013-09-11       Impact factor: 3.390

Review 10.  Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Authors:  Hyeong-Min Lee; Yuna Kim
Journal:  Schizophr Res Treatment       Date:  2016-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.